Try
GeneDx Holdings Corp.
WGSUnited States
50 filed reports · 600 financial concepts · 21 earnings calls · 0 media appearances
Filed reports
50 reports · Sep 2020 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 108 guidance figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Current · 8-KSEC EDGAR | 25 | 104 | Jun 2021 to Jun 2026 |
| Quarterly · 10-QSEC EDGAR | 18 | 3,424 | Sep 2020 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 6 | 3,099 | Dec 2020 to Dec 2025 |
| Annual · 10-K/ASEC EDGAR | 1 | 16 | Dec 2020 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 8-K | Jun 30, 2026 | Aug 3, 2026 | 10 | Open |
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 3, 2026 | 361 | Open |
| FY2026 Q1 | 8-K | Mar 31, 2026 | May 4, 2026 | 10 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 4, 2026 | 232 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 23, 2026 | 951 | Open |
| FY2025 Q4 | 8-K | Dec 31, 2025 | Feb 23, 2026 | 3 | Open |
| FY2025 Q4 | 8-K | Dec 31, 2025 | Jan 12, 2026 | 3 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Oct 28, 2025 | 244 | Open |
| FY2025 Q3 | 8-K | Sep 30, 2025 | Oct 28, 2025 | 4 | Open |
| FY2025 Q2 | 8-K | Jun 30, 2025 | Jul 29, 2025 | 4 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Jul 29, 2025 | 167 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | Apr 30, 2025 | 156 | Open |
Financial data
600 concepts · 6,643 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial580 concepts · 6,026 facts · Dec 2019 to Jul 2026
- Thereafter38 · Sep 2021 to Dec 2025
- Net income loss35 · Dec 2019 to Jun 2026
- Operating income loss34 · Dec 2019 to Jun 2026
- Stockholders equity (US GAAP)34 · Dec 2019 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents33 · Dec 2019 to Jun 2026
- Comprehensive income net of tax33 · Dec 2019 to Jun 2026
- Cost of goods and services sold (US GAAP)33 · Dec 2019 to Jun 2026
- Gross profit (US GAAP)33 · Dec 2019 to Jun 2026
- Nonoperating income expense33 · Dec 2019 to Jun 2026
- Research and development expense33 · Dec 2019 to Jun 2026
- Revenue33 · Dec 2019 to Jun 2026
- General and administrative expense (US GAAP)32 · Dec 2019 to Dec 2025
- Additional paid in capital31 · Sep 2020 to Jun 2026
- Allocated share based compensation expense31 · Dec 2019 to Jun 2026
- Assets31 · Sep 2020 to Jun 2026
- Assets current31 · Sep 2020 to Jun 2026
- Cash and cash equivalents at carrying value31 · Sep 2020 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect31 · Dec 2019 to Jun 2026
- Depreciation depletion and amortization31 · Dec 2019 to Jun 2026
- Income tax expense benefit31 · Dec 2019 to Jun 2026
- Liabilities31 · Sep 2020 to Jun 2026
- Liabilities and stockholders equity31 · Sep 2020 to Jun 2026
- Liabilities current31 · Sep 2020 to Jun 2026
- Net cash provided by used in financing activities31 · Dec 2019 to Jun 2026
Segment15 concepts · 338 facts · Sep 2022 to Jun 2026
- Revenue231 · Sep 2022 to Jun 2026
- Operating Segments39 · Sep 2022 to Jun 2026
- Gross profit (US GAAP)26 · Sep 2022 to Jun 2026
- Allocated share based compensation expense8 · Dec 2022 to Jun 2026
- Depreciation depletion and amortization8 · Dec 2022 to Jun 2026
- Restructuring charges6 · Dec 2022 to Jun 2023
- GeneDx Segment4 · Jun 2025 to Jun 2026
- Asset impairment charges2 · Jun 2025 to Jun 2026
- Income loss from continuing operations before income taxes extraordinary items noncontrolling interest2 · Jun 2025 to Jun 2026
- Income tax expense benefit2 · Jun 2025 to Jun 2026
- Net income loss2 · Jun 2025 to Jun 2026
- Nonoperating income expense2 · Jun 2025 to Jun 2026
- Operating expenses (US GAAP)2 · Jun 2025 to Jun 2026
- Operating income loss2 · Jun 2025 to Jun 2026
- Restructuring costs2 · Jun 2025 to Jun 2026
Product1 concepts · 175 facts · Dec 2019 to Jun 2026
- Revenue175 · Dec 2019 to Jun 2026
Guidance4 concepts · 104 facts · Aug 2021 to Aug 2026
- Revenue Guidance58 · Aug 2021 to Aug 2026
- Gross Margin Guidance34 · Mar 2022 to Aug 2026
- Free Cash Flow Guidance8 · Mar 2023 to Apr 2024
- Net Income Guidance4 · May 2026 to Aug 2026
Segments
513 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments5 members · 338 facts
- Gene Dx167 · Sep 2022 to Jun 2026
- Legacy Sema4102 · Sep 2022 to Sep 2025
- All Other Segments35 · Dec 2023 to Mar 2026
- Legacy Gene Dx22 · Mar 2023 to Jun 2023
- Other12 · Dec 2023 to Dec 2024
Product or service5 members · 175 facts
- Diagnostic Test36 · Dec 2019 to Jun 2026
- Diagnostic Test Institutional Customers36 · Dec 2019 to Jun 2026
- Diagnostic Test Self Pay36 · Dec 2019 to Jun 2026
- Diagnostic Test Third Party Insurance36 · Dec 2019 to Jun 2026
- Product And Service Other31 · Dec 2019 to Jun 2026
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
21 calls · Aug 2021 to Aug 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Aug 3, 2026
- FY2026 Q1May 4, 2026
- FY2025 Q4Feb 23, 2026
- FY2025 Q3Oct 28, 2025
- FY2025 Q2Jul 29, 2025
- FY2025 Q1Apr 30, 2025
- FY2024 Q4Feb 18, 2025
- FY2024 Q3Oct 29, 2024
- FY2024 Q2Jul 30, 2024
- FY2024 Q1Apr 29, 2024
- FY2023 Q4Feb 20, 2024
- FY2023 Q3Nov 4, 2023
- FY2023 Q2Aug 12, 2023
- FY2023 Q1May 14, 2023
- FY2022 Q4Mar 17, 2023
- FY2022 Q3Nov 14, 2022
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.